Pharma major Zydus Cadila on Thursday informed that the company has received final approval from the US drug regulator to market Potassium Citrate ER Tablets used in the prevention of kidney stones.
In a statement, the company informed that it has received final approval from US Food and Drug Administration (USFDA) to market Potassium Citrate ER Tablets 5, 10 and 15 mEq.
The estimated sales in 2014 for Potassium Citrate ER Tablets is USD 131.7 million, as per IMS, the company informed.
The group now has 94 approvals and has so far filed 239 ANDAs since the commencement of the filing process in fiscal 2003-04.